1-tert-Butyl 3-methyl 4-oxopiperidine-1,3-dicarboxylate, 95.0%, 500g

3-Phenylpropyl acetate, 97.0%, 100g

4-Phenoxybenzonitrile, 98.0%, 1g

2-(Piperidin-2-yl)acetic acid hydrochloride, 97%, 1g

[4-(3-Chloro-5-trifluoromethyl-pyridin-2-yl)-pyrimidin-2-ylsulfanyl]-acetic acid, 95.0%, 100mg

2-Bromo-5-phenylpyridine, 95.0%, 5g

iScope IS.1158-PLPHi Biocular for phase contrast with Plan phase IOS objectives and Rackless cross stage (infinity - ergonomic tilting head)

5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-amine, 95.0%, 250mg

2,5-Diaminocyclohexa-2,5-diene-1,4-dione, 98%, 250mg

4-(Bromomethyl)quinoline hydrobromide, 97%, 5g

2-Bromo-3-chloro-5-(trifluoromethyl)pyridine>96.0%(GC)1g

Trimyristin, >95.0%(GC), 1g

Cobalt Naphthenate (Co ca. 8%)500g